Table 4.
Base case results
| rt-CGM | SMBG | Difference | |
|---|---|---|---|
| Cost, GBP | 79,866 | 77,172 | +2694 |
| Treatment costs | 14,691 | 4631 | +10,060 |
| Management costs | 672 | 657 | +15 |
| Cardiovascular complications | 13,898 | 13,929 | –31 |
| Renal complications | 33,696 | 39,619 | –5923 |
| Ulcer/amputation/neuropathy complications | 6496 | 6663 | –168 |
| Opthalmic complications | 10,414 | 10,903 | –490 |
| Severe hypoglycemia | 0 | 715 | –715 |
| Diabetic ketoacidosis | 0 | 54 | –54 |
| Quality-adjusted life expectancy, QALY | 7.897 | 7.166 | +0.731 |
| ICER, GBP per QALY gained | 3684 | ||
| Probability of being cost effective with a WTP threshold of GBP 20,000 (%) | 70.8 | ||
| Probability of being cost saving (%) | 38.7 |
GBP Great British pounds, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, rt-CGM real-time continuous glucose monitoring, SMBG self-monitoring of blood glucose, WTP willingness-to-pay